Li Kang Biomedical Co Ltd (TWO:6242) — Market Cap & Net Worth
Market Cap & Net Worth: Li Kang Biomedical Co Ltd (6242)
Li Kang Biomedical Co Ltd (TWO:6242) has a market capitalization of $33.97 Million (NT$1.08 Billion) as of September 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #23420 globally and #1455 in its home market, demonstrating a -0.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Li Kang Biomedical Co Ltd's stock price NT$33.90 by its total outstanding shares 31807000 (31.81 Million). Also see 6242 total asset value for a full breakdown of the balance sheet.
Li Kang Biomedical Co Ltd Market Cap History: 2015 to 2026
Li Kang Biomedical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $23.23 Million to $33.97 Million (2.55% CAGR). Also see 6242 operating cash flow for how efficiently the company converts equity into cash flow.
Li Kang Biomedical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Li Kang Biomedical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 6242 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.07x
Li Kang Biomedical Co Ltd's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.47x
Li Kang Biomedical Co Ltd's market cap is 0.47 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $26.82 Million | $450.61 Million | $61.51 Million | 0.06x | 0.44x |
| 2017 | $35.84 Million | $495.94 Million | $133.74 Million | 0.07x | 0.27x |
| 2018 | $26.27 Million | $495.57 Million | $76.74 Million | 0.05x | 0.34x |
| 2019 | $25.72 Million | $483.30 Million | $72.02 Million | 0.05x | 0.36x |
| 2020 | $24.97 Million | $456.72 Million | $69.27 Million | 0.05x | 0.36x |
| 2021 | $28.22 Million | $386.97 Million | $51.44 Million | 0.07x | 0.55x |
| 2022 | $43.92 Million | $684.25 Million | $112.09 Million | 0.06x | 0.39x |
| 2023 | $55.61 Million | $629.38 Million | $110.99 Million | 0.09x | 0.50x |
| 2024 | $42.99 Million | $565.51 Million | $77.02 Million | 0.08x | 0.56x |
| 2025 | $39.33 Million | $589.21 Million | $83.82 Million | 0.07x | 0.47x |
Competitor Companies of 6242 by Market Capitalization
Companies near Li Kang Biomedical Co Ltd in the global market cap rankings as of September 18, 2026. Review 6242 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Li Kang Biomedical Co Ltd by market ranking:
- Booking Holdings Inc (NASDAQ:BKNG): Ranked #189 globally with a market cap of $128.79 Billion USD.
- Airbnb Inc (NASDAQ:ABNB): Ranked #406 globally with a market cap of $70.17 Billion USD.
- Royal Caribbean Cruises Ltd (NYSE:RCL): Ranked #421 globally with a market cap of $67.91 Billion USD.
- Trip.com Group Ltd ADR (NASDAQ:TCOM): Ranked #788 globally with a market cap of $34.61 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Booking Holdings Inc | NASDAQ:BKNG | $128.79 Billion | $171.40 |
| #406 | Airbnb Inc | NASDAQ:ABNB | $70.17 Billion | $167.51 |
| #421 | Royal Caribbean Cruises Ltd | NYSE:RCL | $67.91 Billion | $253.92 |
| #788 | Trip.com Group Ltd ADR | NASDAQ:TCOM | $34.61 Billion | $52.95 |
Li Kang Biomedical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Li Kang Biomedical Co Ltd's market cap moved from $23.23 Million to $ 33.97 Million, with a yearly change of 2.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$33.97 Million | -13.63% |
| 2025 | NT$39.33 Million | -8.51% |
| 2024 | NT$42.99 Million | -22.70% |
| 2023 | NT$55.61 Million | +26.62% |
| 2022 | NT$43.92 Million | +55.66% |
| 2021 | NT$28.22 Million | +13.02% |
| 2020 | NT$24.97 Million | -2.93% |
| 2019 | NT$25.72 Million | -2.08% |
| 2018 | NT$26.27 Million | -26.71% |
| 2017 | NT$35.84 Million | +33.62% |
| 2016 | NT$26.82 Million | +15.48% |
| 2015 | NT$23.23 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Li Kang Biomedical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $33.97 Million USD |
| MoneyControl | $33.97 Million USD |
| MarketWatch | $33.97 Million USD |
| marketcap.company | $33.97 Million USD |
| Reuters | $33.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. produces and sells pharmaceuticals, beauty products, and health food. It offers Chinese and Western medicines, nutritional supplements, beauty and skincare products, and daily necessities products. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was fou… Read more